Hyloris Pharmaceuticals SA reported consolidated earnings results for the half year ended June 30, 2021. For the period, revenue was €838,000 against €82,000 a year ago. Operating loss was €7,913,000 against €3,633,000 a year ago. Loss of the period was €8,240,000 against €3,742,000 a year ago. Basic and diluted loss per share was €0.32 against €0.21 a year ago.